Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up the in-house production of small molecule drugs.
An approvable letter for Shire's long-lasting formulation of its
best-selling attention deficit and hyperactivity disorder (ADHD)
drug Adderall is not the stumbling block it may appear says the
Shire, Britain's third-biggest drugmaker, has won approval in the
US for Daytrana, a methylphenidate skin patch developed with
Noven's transdermal technology, making it the first non-oral
medication for the treatment of...
Supernus Pharmaceuticals has acquired the drug formulation business
of Shire Laboratories (SLI) in a move that strengthens the
pharmaceutical technologies and services. The company will make use
of the patents to improve its own portfolio...